Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.
Data shows investigational iptacopan improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3G 1 ; Phase III clinical trial to start in 2021 Results add to body of information on iptacopan, with previous interim analysis data from same trial showing significant reduction in proteinuria, improv
Tabrecta (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data 1,2 Tabrecta achieved 65.6% overall response rate (ORR) in first-line and 51.6% in second-line settings in new expansion cohort analysis o
Men who received 177 Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression or death (median rPFS benefit of 5 months) compared to best standard of care alone 1 - Significant improvement demonstrated in all key secondary endpo
Phase III JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms 1 ) vs. placebo (P<.001) in pediatric patients with two subtypes of juvenile idiopathic arthritis (JIA) 2 JIA has limited treatment options and affects approximately 2 million children worldwide 3,4 .
MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS benefit demonstrated for premenopausal women as shown in MONALEESA-7 1, 2 The relative risk reduction of death by 36% in the MONALEESA-3 first
Phase II primary endpoint results for investigational iptacopan in IgAN demonstrated effective and clinically meaningful reduc tion of proteinuria 1 - a key risk predictor in kidney disease progression 2 Iptacopan also showed a trend toward stabilization of kidney function 1 ; Phase III clinical trial APPLAUSE is underway There are no currently
Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell carcinoma after prior systemic therapy 1 Additional Phase II data presented at ASCO showed tislelizumab demonstrated durable anti-tumor activity in pa
At final analysis, study showed clinically relevant improvement in median overall survival with a difference of 11.7 months between arms (Hazard ratio (HR): 0.84 with 95% CI: (0.60, 1.17) (p=0.30, two-sided)) 1 No new safety signals emerged in long-term follow-up with median of 6.3 years; safety profil
Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion 1 Robust response observed in heavily pretreated patients in critical need of a potentially definitive treatment option 1, 2 No patients in ELARA trial experienced grade 3/4 cytokine release syndrome, the most co
Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials and is consistent with the established